BioAge Labs Initiates Phase 1 Trial of Novel NLRP3 Inhibitor BGE-102 for Obesity Treatment
BioAge Labs, a clinical-stage biotechnology company based in Emeryville, California, has announced the initiation of a Phase 1 clinical study of BGE-102, an orally available, brain-penetrant small molecule NLRP3 inhibitor being developed for the treatment of obesity.
Clinical Trials | 16/09/2025 | By Dineshwori | 263
Akeso Doses First Patient in Global Trial of Cadonilimab for PD-1 Resistant Liver Cancer
COMPASSION-36, the first global Phase III trial of Cadonilimab, is underway in China, the US, and Europe. It marks a key step in Akeso's effort to advance cancer immunotherapy beyond single-target treatments.
Clinical Trials | 15/09/2025 | By Dineshwori | 275
Phrontline Biopharma Announces First Patient Dosed in Phase-I Clinical Trial of TJ101
The Phase 1 study of TJ101 will assess its safety, tolerability, pharmacokinetics, and early anti-tumor activity in various solid tumors, using a dose escalation and expansion cohort design.
Clinical Trials | 15/09/2025 | By Dineshwori | 153
NMPA Clears Zhimeng Biopharma's Drug for Phase-II Epilepsy Trial
Zhimeng Biopharma’s drug for Phase II epilepsy trial will be evaluated in a randomized, double-blind, placebo-controlled multinational study to test its efficacy, safety, and tolerability as an adjunct therapy in adults with focal epilepsy.
Clinical Trials | 13/09/2025 | By Dineshwori | 231
Modular Medical Completes MODD1 Clinical Study, Advances Toward Next-Gen Pivot Pump Launch
US-based insulin delivery technology company Modular Medical has announced the successful completion of a clinical study with its MODD1 pump.
Clinical Trials | 12/09/2025 | By Dineshwori | 405
Sanofi Drug Earns Fast Track Status for Wet AMD in US
Sanofi is evaluating SAR402663 in a Phase 1/2 trial (NCT06660667) for neovascular AMD. The gene therapy targets abnormal blood vessel growth, reduces retinal damage, and aims to eliminate the need for frequent intravitreal injections.
Clinical Trials | 11/09/2025 | By Dineshwori | 224
Lilly Drug Jaypirca Delivers Positive Results in CLL Patients
Lilly’s Jaypirca showed a strong Progression-Free Survival (PFS) benefit in front-line CLL, with data from BRUIN studies set to support global label expansion filings.
Clinical Trials | 10/09/2025 | By Dineshwori | 171
Amgen and Kyowa Kirin Report Phase-III Results for Rocatinlimab in Atopic Dermatitis
Amgen and Kyowa Kirin report top-line results from ongoing ASCEND study evaluating Rocatinlimab’s long-term safety and efficacy in adults with moderate to severe Atopic Dermatitis following prior ROCKET trials.
Clinical Trials | 09/09/2025 | By Dineshwori | 259
Mankind Pharma Gets CDSCO Nod to Begin Phase 1 Trials of Novel Autoimmune Drug Candidate MKP11093
Mankind Pharma Ltd., India’s 4th largest pharmaceutical company, today announced that it has received approval from the Central Drugs Standard Control Organisation (CDSCO) to initiate a Phase 1 clinical trial of MKP11093, a novel, orally administered Janus kinase-1 (JAK-1) inhibitor.
Clinical Trials | 08/09/2025 | By Darshana | 187
Medtronic Hugo Robotic System Shows Success in Hernia Repair
Medtronic’s Enable Hernia Repair study marks the first IDE clinical trial in the US for robotic-assisted hernia surgery, evaluating the Hugo RAS system in inguinal and ventral procedures.
Clinical Trials | 06/09/2025 | By Dineshwori | 288
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy